… the intravenous (IV) drug for patients with Covid-19 with worsening … remdesivir after 11 days
of the disease onset. The other patient was mechanically ventilated and received remdesivir …

… the use of remdesivir in patients hospitalised with COVID-19. The aim of this analysis was
to assess the benefits and harms of remdesivir for these patients and whether treatment effects …

… 13 544 patients, were included in this meta-analysis. Among them… patients were assigned
to the 10 day and 5 day remdesivir regimens, respectively. Patients receiving 5 day remdesivir …

… 5-day remdesivir group and 10-day remdesivir group compared … 5-day remdesivir group
compared to the 10-day remdesivir … analysis demonstrated that the use of remdesivir for patients …

… the use of remdesivir to treat COVID-19 patients have shown … use of remdesivir for the
treatment of patients hospitalized … on hospitalized patients in the present meta-analysis. On the …

… The clinical output comparison of the 5-day and 10-day remdesivir … meta-analysis provided
an updated evaluation of scientific evidence on the use of remdesivir in COVID-19 patients. …

… the efficacy and safety of remdesivir for the treatment of COVID… use of remdesivir as a treatment
in patients with COVID-19. … the use of remdesivir for the treatment of COVID-19 patients is …

… remdesivir compared to a 10‐day course of remdesivir (pooled RR=0.73; 95% CI, 0.40–1.33)
(Figure 1C). Our metaanalysis … days of administration of remdesivir but absence of mortality …

… This systematic review and meta-analysis aimed to provide comprehensive evidence
regarding the clinical benefits and safety profile of remdesivir in hospitalised patients with COVID‐…

… absolute differences in mortality between remdesivir and control patients were generated,
and we integrated the area under the curve to obtain the probability for any mortality benefit …